What Made Chardan Capital Downgrade 4d Pharma’s Stock?

In a report released today, Keay Nakae from Chardan Capital downgraded 4d Pharma (LBPSResearch Report) to Hold. The company’s shares closed last Friday at $1.65, close to its 52-week low of $1.50.

According to, Nakae is a 4-star analyst with an average return of 6.3% and a 40.1% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Sonnet BioTherapeutics Holdings, Better Therapeutics, Inc., and Arrowhead Pharmaceuticals.

4d Pharma has an analyst consensus of Hold.

See Insiders’ Hot Stocks on TipRanks >>

4d Pharma’s market cap is currently $36.89M and has a P/E ratio of -0.43.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

4d pharma PLC and its subsidiaries are in the business of research and development and production of live biotherapeutic products. The company develops biotherapeutic products for diseases such as cancer, asthma, autism, and autoimmune conditions such as arthritis and multiple sclerosis. Its developing science includes Live biotherapeutics, Microbiome, MicroRx, MicroDx, and others.

Read More on LBPS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed